Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjögren's syndrome

Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial

(2012) Rodney P E Pollard et al.   ANNALS OF THE RHEUMATIC DISEASES

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells

(2012) Tom A. Barr et al.   JOURNAL OF EXPERIMENTAL MEDICINE

B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: A double-blind, placebo-controlled study

(2011) W. H. Abdulahad et al.   ARTHRITIS AND RHEUMATISM

What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?

(2011) Cees GM Kallenberg et al.   ARTHRITIS RESEARCH & THERAPY

Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial

(2010) J. M. Meijer et al.   ARTHRITIS AND RHEUMATISM

The Detrimental Effects of IFN-  on Vasculogenesis in Lupus Are Mediated by Repression of IL-1 Pathways: Potential Role in Atherogenesis and Renal Vascular Rarefaction

(2010) S. G. Thacker et al.   JOURNAL OF IMMUNOLOGY

Cytokines in Sjögren’s syndrome

(2009) N Roescher et al.   ORAL DISEASES

Cytokine and autoantibody profiling related to histopathological features in primary Sjogren's syndrome

(2009) T. R. Reksten et al.   RHEUMATOLOGY